Navigation Links
Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models

    - Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By

                     90% In a Preclinical Cancer Model -

- Peregrine's Antibodies that Selectively Inhibit VEGF Receptor 2 Could

Potentially Have Advantages over Non-Selective Approaches -

- These Results Along with Data Presented on a Fully Human Antibody Support

Advancing Peregrine's Anti-VEGF Program towards Clinical Trials -

LOS ANGELES and TUSTIN, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer. In this model, treatment with 2C3 reduced the growth of pancreatic tumors by 90%. The researchers also assessed the anti-tumor activity of 2C3 and the marketed anti-cancer agent Avastin(R) in a number of preclinical cancer models. The anti-tumor activity of 2C3, which only blocks VEGF receptor 2 (VEGFR2) compared favorably to that of Avastin, which blocks VEGF binding to both VEGF receptor 1 (VEGFR1) and VEGFR2.

VEGF is a primary stimulant of the development and maintenance of the blood vessels needed by tumors to survive and grow. It is thought to work by binding to and activating two receptors that are expressed on endothelial and other types of cells. The series of studies reported today tested the hypothesis that selectively inhibiting VEGFR2 is an equally effective anti-tumor strategy to blocking both receptors. Most of t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... , Aug. 29, 2014  Chuma Holdings, ... financing alternatives and turnkey support services for the ... that FINRA processed and approved the Company,s name ... 2014, CannaMed Corporation will be known as Chuma ... was accomplished through a merger with the Company,s ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
(Date:8/29/2014)... 30, 2014 UWDress.com, one of the ... its latest collection of 2014 floor length bridesmaid ... for these wonderful items. According to the company’s marketing ... a greatly discounted rate (up to 60 percent off) ... products has a special neckline: strapless, one-shoulder, bateau and ...
(Date:8/29/2014)... USA (PRWEB) August 29, 2014 According ... May Reduce Painkiller Overdoses (8/25), a new study ... help reduce pain have seen a significant decrease in ... certificate information over a ten year period, and comparing ... were able to find that there was about a ...
(Date:8/29/2014)... 2014 As reported by WKMS.com in the ... an Ohio municipal court drug has come up with a ... who serves as the presiding judge in a Southeastern Ohio ... offer addicts a medicated treatment option that can literally prevent ... known as Vivitrol, which blocks receptors in the brain that ...
(Date:8/29/2014)... reported by CNN.com in the article Prescription Drug Abuse: ... you need help for a prescription drug abuse problem can ... that if you simply try to find general help for ... the information that is available online. Although the information available ... possible to get help. The statistics from SAMSHA remind the ...
(Date:8/29/2014)... As reported by GantDaily.com in the article NIDA Switches ... (8/20), the National Institute on Drug Abuse is taking new ... turning to social media. As NIDA currently relies on community ... with the University of Maryland to create a monitoring system ... be funded by the National Institute of Health. The project ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3
... where endometrial tissue, which is normally found only in ... // and attaches itself to ligaments and organs in ... include pain, bleeding, inflammation, adhesions and infertility. ... with endometriosis are at higher risk of having migraines. ...
... be a strong link between Skin Allergies and cancer. People who ... blood related caners as they grow older. A Swedish team of ... of the BMC public Health. ,In this alarming finding ... likely to develop Leukemia and those of us who have ...
... studying around 700,000 people researchers say dads who have ... risk // for developing schizophrenia later in life. ... admitted to the hospital in Sweden between 1989 and ... psychosis. Researchers say they found a strong association between ...
... samples for viral RNA among organ and tissue donors who ... // transmission among transplant recipients, say researchers according to a ... diseases such as HIV or hepatitis C is the usual ... may be infected with a virus but show a full ...
... suffer from sleep apnea run a higher risk of complications ... apnea is a condition in which patients stop breathing periodically ... the condition, known as obstructive sleep apnea, affects as many ... of all middle-aged women. ,Researchers say 80 percent of ...
... to gain complete control of their condition, say researchers ... uncontrolled asthma. Some of the patients had never before ... on a low-dose inhaled steroid; and some were on ... were randomly assigned to receive either the inhaled steroid ...
Cached Medicine News:
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: